Department of Anesthesiology and Pain Management, Beijing Tiantan Hospital, Capital Medical University, China.
Clinical Trial and Research Center for Stroke, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China.
Pain Physician. 2018 Sep;21(5):469-481.
Trigeminal neuralgia (TN) is a neurological syndrome characterized by paroxysmal, lightning-like, severe pain in the facial area innervated by the trigeminal nerve. Patients who do not respond well to drug treatment can undergo a nerve block, a traditional conservative treatment. Pulsed radiofrequency (PRF) is a nondestructive pain intervention technique. However, its treatment effectiveness for TN has rarely been reported and remains controversial among scholars. A recent single-center preliminary clinical study showed that high-voltage PRF was significantly effective in the treatment of TN. However, whether high-voltage PRF is a viable pain treatment option for TN patients who are unresponsive to drug treatment must still be confirmed with standardized clinical studies by utilizing conservative nerve block treatment as a control.
To compare the effectiveness and safety of high-voltage PRF and nerve block for primary TN patients who have failed to respond to pharmacological treatment and who are seeking a better non-surgical treatment option.
Prospective, multicenter, randomized, double-blind, controlled clinical trial.
Three interventional pain management centers in Beijing, China.
The study will include 134 consecutive patients with primary TN who have failed to respond to drug treatment. The patients will be randomly assigned to 2 groups, the nerve block group and the PRF group. The nerve block group will be slowly injected with 1.4 mL of a mixture of dexamethasone and lidocaine after 360 s of sham PRF treatment, and 0.5 mL of normal saline will be administered before the needle is withdrawn. The PRF group will undergo 360 s of 42°C PRF treatment at the highest output voltage that the patients can tolerate, after which the patients will be injected with the same concentration and volume of lidocaine and normal saline that the nerve block group receives. The Barrow Neurological Institute (BNI) pain intensity scale will be used to assess the degree of pain relief before and after the treatment.
The effectiveness and safety of high-voltage PRF and nerve block to treat TN will be analyzed to determine significant differences in pain relief and functional improvement. The primary efficacy outcome measure is the response rate at one-year post-operation (BNI I-III/total number of cases∗100%). Secondary efficacy outcome measures include the response rate at postoperative day 1, week 1, week 2, month 1, month 3, month 6 and year 2, the patient satisfaction score (PSS) at various time points, the dosage of antiepileptic drugs (milligrams per day), and information regarding patients with a BNI score of IV or V who switch to other therapies.
The effects of the waveform, treatment duration, frequency and other parameters of PRF deserve further investigation.
This is the first multicenter, double-blind, randomized controlled study to compare the efficacy and safety of PRF and nerve block to treat TN patients who have failed to respond to drug treatment. Moreover, the value of PRF in TN treatment may need to be clinically clarified with evidence-based medical support and other advanced studies.
Trigeminal neuralgia, effectiveness, safety, pulsed radiofrequency.
三叉神经痛(TN)是一种神经系统综合征,其特征是面部区域出现阵发性、闪电样、剧烈疼痛,这些面部区域由三叉神经支配。对药物治疗反应不佳的患者可以进行神经阻滞,这是一种传统的保守治疗方法。脉冲射频(PRF)是一种非破坏性的疼痛干预技术。然而,其治疗 TN 的效果很少有报道,学者们对此仍存在争议。最近的一项单中心初步临床研究表明,高压 PRF 对 TN 的治疗效果显著。然而,对于药物治疗反应不佳的 TN 患者,高压 PRF 是否是一种可行的疼痛治疗选择,仍需要利用保守的神经阻滞治疗作为对照,通过标准化的临床研究来证实。
比较高压 PRF 和神经阻滞治疗原发性 TN 患者的有效性和安全性,这些患者对药物治疗无反应,正在寻求更好的非手术治疗选择。
前瞻性、多中心、随机、双盲、对照临床试验。
中国北京的 3 个介入性疼痛管理中心。
这项研究将包括 134 名连续原发性 TN 患者,这些患者对药物治疗无反应。患者将被随机分配到 2 组,即神经阻滞组和 PRF 组。神经阻滞组将在 360 s 的假 PRF 治疗后缓慢注入 1.4 mL 地塞米松和利多卡因的混合物,在拔出针头前注入 0.5 mL 生理盐水。PRF 组将在能耐受的最高输出电压下进行 360 s 的 42°C PRF 治疗,然后注入与神经阻滞组相同浓度和体积的利多卡因和生理盐水。巴罗神经研究所(BNI)疼痛强度量表将用于评估治疗前后的疼痛缓解程度。
将分析高压 PRF 和神经阻滞治疗 TN 的有效性和安全性,以确定疼痛缓解和功能改善方面的显著差异。主要疗效指标为术后 1 年的反应率(BNI I-III/总病例数∗100%)。次要疗效指标包括术后第 1、1 周、第 2 周、第 1 个月、第 3 个月、第 6 个月和第 2 年的反应率、各时间点的患者满意度评分(PSS)、抗癫痫药物(毫克/天)的剂量以及 BNI 评分为 IV 或 V 的患者转为其他治疗的信息。
PRF 的波形、治疗持续时间、频率和其他参数的影响值得进一步研究。
这是第一项多中心、双盲、随机对照研究,比较了 PRF 和神经阻滞治疗药物治疗反应不佳的 TN 患者的疗效和安全性。此外,PRF 在 TN 治疗中的价值可能需要通过循证医学支持和其他先进研究来临床阐明。
三叉神经痛,疗效,安全性,脉冲射频。